Finerenone was analyzed to assess if it lowers blood pressure and if its cardiovascular benefits in HFmrEF or HFpEF depend on baseline blood pressure or blood pressure reduction.
Does finerenone lower blood pressure and do its cardiovascular benefits depend on baseline blood pressure or blood-pressure reduction in patients with mildly reduced or preserved ejection fraction heart failure?
This trial investigates the blood pressure-lowering effects of finerenone and their relationship to cardiovascular outcomes in patients with HFmrEF or HFpEF.
This randomized clinical trial analyzes whether finerenone lowers blood pressure and whether its cardiovascular benefits in patients with mildly reduced or preserved ejection fraction heart failure depend on baseline blood pressure or blood-pressure reduction.
“This FINEARTS-HF analysis supports the use of finerenone to improve cardiovascular outcomes across a broad BP spectrum in HFmrEF/HFpEF.”
Ostrominski et al. (2026) studied this question. Finerenone was analyzed to assess if it lowers blood pressure and if its cardiovascular benefits in HFmrEF or HFpEF depend on baseline blood pressure or blood pressure reduction.